Astellas Pharma Inc is making significant strides across various areas. It has announced the launch of a new Life Sciences Center in Cambridge, Massachusetts, aimed at facilitating breakthrough medicine discovery. The company has also been awarded FDA listing for DIGITIVA™, a heart failure management drug, and has received approval for its gastric cancer therapy from the UK regulator. Astellas has entered into multiple research-related collaborations, including with YASKAWA for developing a cell therapy ecosystem and with Poseida Therapeutics for novel allogeneic cell therapies in oncology. Financial updates include a strategic collaboration with Mass General Brigham and a completed acquisition of Propella Therapeutics. Meanwhile, Astellas' PADCEV™ has received positive CHMP opinion and approval from the European Commission for the treatment of advanced bladder cancer. Despite facing a legal hurdle from an employee indictment in China, the company remains committed to innovative measures such as their digital campaign aimed at patient value. Astellas has also seen executive changes with the appointment of Michael Petroutsas as Head of US Commercial.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Fri, 20 Sep 2024 07:00:00 GMT -
Rating 8
- Innovation 7
- Rumor 3
